Gene Panel Market Segmentation:
Design Segment Analysis
The predesigned gene panels segment is anticipated to garner 45.3% of the market share by 2037. The segment growth is fueled by strong adoption from the hospitals and widespread usage for cancer risk screening. Their standardized formats are fostering the speedy regulatory approval and implementation in public healthcare. The bulk purchasing from the hospitals and labs is further fueling the segment's growth. The pre-optimized assays need less validation, which is fostering the widespread adoption in labs. Also, the advent of the AI-curated panels and liquid biopsy-based panels is further accelerating adoption.
Technique Segment Analysis
The amplicon-based NGS panels segment is anticipated to register 35.4% market share owing to the faster turnaround time and its suitability for high-volume labs. The amplicon-based panels need fewer DNA inputs and have less complex library preparation in comparison with the hybrid capture. Also, these panels are ideal for the small to medium gene sets and well-suited for the focused panels. The amplicon PCR usability is increasing due to its same-day library preparation and capability to lower the downtime by 3-5 days.
Our in-depth analysis of the gene panel market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Technique |
|
|
Design |
|
|
Application |
|
|
End user |
|
